1. Home
  2. LEGN vs ICL Comparison

LEGN vs ICL Comparison

Compare LEGN & ICL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • ICL
  • Stock Information
  • Founded
  • LEGN 2014
  • ICL 1968
  • Country
  • LEGN United States
  • ICL Israel
  • Employees
  • LEGN N/A
  • ICL N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • ICL Agricultural Chemicals
  • Sector
  • LEGN Health Care
  • ICL Industrials
  • Exchange
  • LEGN Nasdaq
  • ICL Nasdaq
  • Market Cap
  • LEGN 7.0B
  • ICL 8.1B
  • IPO Year
  • LEGN 2020
  • ICL N/A
  • Fundamental
  • Price
  • LEGN $30.71
  • ICL $6.76
  • Analyst Decision
  • LEGN Strong Buy
  • ICL Hold
  • Analyst Count
  • LEGN 13
  • ICL 2
  • Target Price
  • LEGN $79.42
  • ICL $6.75
  • AVG Volume (30 Days)
  • LEGN 1.5M
  • ICL 638.4K
  • Earning Date
  • LEGN 05-13-2025
  • ICL 05-19-2025
  • Dividend Yield
  • LEGN N/A
  • ICL 2.73%
  • EPS Growth
  • LEGN N/A
  • ICL N/A
  • EPS
  • LEGN N/A
  • ICL 0.32
  • Revenue
  • LEGN $627,241,000.00
  • ICL $6,841,000,000.00
  • Revenue This Year
  • LEGN $65.96
  • ICL $4.71
  • Revenue Next Year
  • LEGN $52.55
  • ICL $4.08
  • P/E Ratio
  • LEGN N/A
  • ICL $21.90
  • Revenue Growth
  • LEGN 119.97
  • ICL N/A
  • 52 Week Low
  • LEGN $29.27
  • ICL $3.79
  • 52 Week High
  • LEGN $60.87
  • ICL $6.84
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 39.14
  • ICL 59.08
  • Support Level
  • LEGN $30.25
  • ICL $6.75
  • Resistance Level
  • LEGN $33.30
  • ICL $6.95
  • Average True Range (ATR)
  • LEGN 1.50
  • ICL 0.11
  • MACD
  • LEGN -0.19
  • ICL -0.01
  • Stochastic Oscillator
  • LEGN 25.12
  • ICL 45.22

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About ICL ICL Group Ltd.

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North and South America, and the Rest of the world.

Share on Social Networks: